Shots:
- Trial assessed Lilly‘s VERVE-102 (IV; 0.3, 0.45, 0.6, 0.7, 0.8 & 1mg/kg) in 35 adults with HeFH or premature coronary artery disease who required additional LDL-C lowering despite maximally tolerated oral lipid-lowering therapy
- Single infusion of VERVE-102 led to dose-dependent PCSK9 reductions of 51% (0.3mg/kg) to 88% (1mg/kg), with corresponding mean LDL-C reductions of 9% (0.3mg/kg), 44% (0.45mg/kg), 45% (0.6mg/kg), 33% (0.7mg/kg), 51% (0.8mg/kg), & 62% (1mg/kg); effects were sustained for ~18mos. post-treatment
- Data on VERVE-102 were presented at EAS’26 & published in The NEJM, with Lilly planning to initiate the P-II study by year-end
Ref: Eli Lilly | Image: Eli Lilly | Press Release
Related News: Eli Lilly Reports P-III (TRIUMPH-1) Trial Data on Retatrutide for Weight Management
PharmaShots, your go-to media platform for customized news ranging across multiple indications. For more information, connect with us at connect@pharmashots.com
